University of Sydney acquires state-of-the-art MILabs preclinical in-vivo X-ray CT

//University of Sydney acquires state-of-the-art MILabs preclinical in-vivo X-ray CT

University of Sydney acquires state-of-the-art MILabs preclinical in-vivo X-ray CT

Sydney, Australia, and Utrecht, the Netherlands, August 31st, 2018

MILabs announces that it has successfully completed the installation of its next-generation Adaptive U-CTXUHR at Sydney Imaging, a Core Research Facility of the University of Sydney. Recognizing that excellence in research is increasingly linked to excellence in infrastructure capability, Sydney Imaging selected MILabs X-ray CT system for its unprecedented dose-efficiency for in vivo imaging of a wide variety of in vivo animal models of human diseases, from mice to rabbits.  The system offers a unique combination of very low-dose, fast and high-resolution diagnostic X-ray CT and can, at any time, be upgraded to molecular CT imaging.

Prof. Fernando Calamante, Director of Sydney Imaging explained, “This new Adaptive CT system represents a significant contribution to our expanding set of biomedical imaging equipment at Sydney Imaging, and provides a powerful complementary tool to drive innovation and translational research. It reflects the University’s long-term strategic plan of providing state-of-the-art research infrastructure, as platforms for collaboration.”

Prof. F. Beekman, CEO/CSO MILabs B.V. added: “We are delighted to add Sydney Imaging to our fast growing user-base of Adaptive CT systems. We are looking forward to work with this core biomedical imaging facility to further accelerate its research programs, and to further adapt the system for molecular imaging applications if the need develops”.

Trent Warburton,  Managing Director at TrendBio, MILabs’ exclusive Australian distributor,  stated, “We are particularly pleased to be able to provide the MILabs advanced preclinical imaging technologies to the Australian scientific community and in particular into a core research facility at the University of Sydney”.

MILabs Adaptive CT combines cutting-edge CMOS technology with a thick scintillation layer to efficiently convert low-dose X-rays to CT images. With dual-gating capabilities and on-the-fly readout, the system sets new low-dose benchmarks without compromising image quality for all in-vivo CT imaging applications.

About:

Sydney Imaging, University of Sydney offers world-class imaging capabilities and academic expertise. Sydney Imaging is a unique facility for research and education in the field of biomedical science and offers preclinical and clinical modalities, and a world-class hybrid theatre providing the capability for translational research along with training and development of specialized imaging skills. Sydney Imaging is located at the University of Sydney’s Charles Perkins Centre and Brain and Mind Centre. For more information, visit: https://sydney.edu.au/research/facilities/sydney-imaging.html

TrendBio (Melbourne, Australia) is a specialized instrument and consumable supplier servicing the Australian and New Zealand scientific markets. With products from market leaders across the divisions of Imaging, Genomics, Proteomics, Cell Biology, Biologics, and Chemistry. As a leading supplier, TrendBio provides high-level support covering technical, applications and sales. For more information, visit http://www.trendbio.com.au

MILabs B.V. (Utrecht, the Netherlands) provides high-end integrated multimodality imaging solutions for biomedical and pharmaceutical research, designed to deliver high-definition molecular, functional and anatomical images. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. For more information, visit  www.milabs.com or contact MILabs at info@milabs.com

2018-09-05T12:27:31+00:00September 3rd, 2018|News|0 Comments